دورية أكاديمية
Amiodarone and Thyroid Dysfunction ; Amiodaron i tiroidna disfunkcija
| العنوان: | Amiodarone and Thyroid Dysfunction ; Amiodaron i tiroidna disfunkcija |
|---|---|
| المؤلفون: | Medić, Filip, Bakula, Miro, Alfirević, Maša, Bakula, Maja, Mucić, Katarina, Marić, Nikolina |
| المصدر: | Acta clinica Croatica ; ISSN 0353-9466 (Print) ; ISSN 1333-9451 (Online) ; Volume 61. ; Issue 2 |
| سنة النشر: | 2022 |
| المجموعة: | Hrčak - Portal of scientific journals of Croatia / Portal znanstvenih časopisa Republike Hrvatske |
| مصطلحات موضوعية: | Amiodarone, Thyroid dysfunction, Amiodarone-induced hypothyroidism, Amiodarone-induced thyrotoxicosis, Amiodaron, Tireoidna disfunkcija, Amiodaronom izazvana hipotireoza, Amiodaronom izazvana tireotoksikoza |
| الوصف: | Thyroid gland has a key role in maintaining the body homeostasis. Thyroxine is the main hormone secreted from the thyroid gland, its effect being predominantly achieved after the intracellular conversion of thyroxine to triiodothyronine, which exhibits a higher affinity for the receptor complex, thus modifying gene expression of the target cells. Amiodarone is one of the most commonly used antiarrhythmics in the treatment of a broad spectrum of arrhythmias, usually tachyarrhythmias. Amiodarone contains a large proportion of iodine, which is, in addition to the intrinsic effect of the medication, the basis of the impact on thyroid function. It is believed that 15%-20% of patients treated with amiodarone develop some form of thyroid dysfunction. Amiodarone may cause amiodarone-induced hypothyroidism (AIH) or amiodarone-induced thyrotoxicosis (AIT). AIT is usually developed in the areas with too low uptake of iodine, while AIH is developed in the areas where there is a sufficient iodine uptake. Type 1 AIT is more common among patients with an underlying thyroid pathology, such as nodular goiter or Graves’ (Basedow’s) disease, while type 2 mostly develops in a previously healthy thyroid. AIH is more common in patients with previously diagnosed Hashimoto’s thyroiditis. Combined types of the diseases have also been described. Patients treated with amiodarone should be monitored regularly, including laboratory testing and clinical examinations, to early detect any deviations in the functioning of the thyroid gland. Supplementary levothyroxine therapy is the basis of AIH treatment. In such cases, amiodarone therapy quite often need not be discontinued. Type 1 AIT is treated with thyrostatic agents, like any other type of thyrotoxicosis. If possible, the underlying amiodarone therapy should be discontinued. In contrast to type 1 AIT, the basic pathophysiological substrate of which is the increased synthesis and release of thyroid hormones, the basis of type 2 AIT is destructive thyroiditis caused by amiodarone, ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://hrcak.srce.hr/285013Test |
| الإتاحة: | https://doi.org/10.20471/acc.2022.61.02.20Test https://hrcak.srce.hr/285013Test https://hrcak.srce.hr/file/412578Test |
| حقوق: | info:eu-repo/semantics/openAccess ; https://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: | edsbas.41D7A0C5 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |